MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of … – GlobeNewswire (press release)
|
MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of …
GlobeNewswire (press release) SurVaxM is an immunotherapy that was discovered at Roswell Park Comprehensive Cancer Center and is being developed by MimiVax. It targets survivin, a cell-survival protein present in most cancers, and is designed to control tumor growth and recurrence. |
